The EGFR C797S mutation in TKI-naive NSCLC - de novo EGFR C797S mutation in NSCLC

o concurrent C797S mutation with known EGFR gene mutation was identified. T790M mutation was identified in 12 patients (4.9%). ERBB2 or MET gene amplification was found in a few patients (0.0-0.4%). MDM2 gene amplification was associated with tumor recurrence and shorter progression free survival for first or second generation EGFR-TKIs.